-
Je něco špatně v tomto záznamu ?
Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer
K. Veselá, Z. Kejík, M. Masařík, P. Babula, P. Dytrych, P. Martásek, M. Jakubek
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
PubMed
39539276
DOI
10.1021/acsptsci.4c00518
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Head and neck cancers (HNC) are aggressive, difficult-to-treat tumors that can be caused by genetic factors but mainly by lifestyle or infection caused by the human papillomavirus. As the sixth most common malignancy, it presents a formidable therapeutic challenge with limited therapeutic modalities. Curcumin, a natural polyphenol, is appearing as a promising multitarget anticancer and antimetastatic agent. Numerous studies have shown that curcumin and its derivatives have the potential to affect signaling pathways (NF-κB, JAK/STAT, and EGFR) and molecular mechanisms that are crucial for the growth and migration of head and neck tumors. Furthermore, its ability to interact with the tumor microenvironment and trigger the immune system may significantly influence the organism's immune response to the tumor. Combining curcumin with conventional therapies such as chemotherapy or radiotherapy may improve the efficacy of treatment and reduce the side effects of treatment, thereby increasing its therapeutic potential. This review is a comprehensive overview that discusses both the benefits and limitations of curcumin and its therapeutic effects in the context of tumor biology, with an emphasis on molecular mechanisms in the context of HNC. This review also includes possibilities to improve the limiting properties of curcumin both in terms of the development of new derivatives, formulations, or combinations with conventional therapies that have potential as a new type of therapy for the treatment of HNC and subsequent use in clinical practice.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002182
- 003
- CZ-PrNML
- 005
- 20250123102011.0
- 007
- ta
- 008
- 250117s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acsptsci.4c00518 $2 doi
- 035 __
- $a (PubMed)39539276
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Veselá, Kateřina $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic $1 https://orcid.org/0000000229088101
- 245 10
- $a Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer / $c K. Veselá, Z. Kejík, M. Masařík, P. Babula, P. Dytrych, P. Martásek, M. Jakubek
- 520 9_
- $a Head and neck cancers (HNC) are aggressive, difficult-to-treat tumors that can be caused by genetic factors but mainly by lifestyle or infection caused by the human papillomavirus. As the sixth most common malignancy, it presents a formidable therapeutic challenge with limited therapeutic modalities. Curcumin, a natural polyphenol, is appearing as a promising multitarget anticancer and antimetastatic agent. Numerous studies have shown that curcumin and its derivatives have the potential to affect signaling pathways (NF-κB, JAK/STAT, and EGFR) and molecular mechanisms that are crucial for the growth and migration of head and neck tumors. Furthermore, its ability to interact with the tumor microenvironment and trigger the immune system may significantly influence the organism's immune response to the tumor. Combining curcumin with conventional therapies such as chemotherapy or radiotherapy may improve the efficacy of treatment and reduce the side effects of treatment, thereby increasing its therapeutic potential. This review is a comprehensive overview that discusses both the benefits and limitations of curcumin and its therapeutic effects in the context of tumor biology, with an emphasis on molecular mechanisms in the context of HNC. This review also includes possibilities to improve the limiting properties of curcumin both in terms of the development of new derivatives, formulations, or combinations with conventional therapies that have potential as a new type of therapy for the treatment of HNC and subsequent use in clinical practice.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kejík, Zdeněk $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic
- 700 1_
- $a Masařík, Michal $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic $1 https://orcid.org/0000000311727195 $7 xx0104244
- 700 1_
- $a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
- 700 1_
- $a Dytrych, Petr $u First Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 2, 121 08 Prague, Czech Republic
- 700 1_
- $a Martásek, Pavel $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic
- 700 1_
- $a Jakubek, Milan $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague 2, Czech Republic
- 773 0_
- $w MED00210754 $t ACS pharmacology & translational science $x 2575-9108 $g Roč. 7, č. 11 (2024), s. 3394-3418
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39539276 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123102005 $b ABA008
- 999 __
- $a ok $b bmc $g 2254495 $s 1238185
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 7 $c 11 $d 3394-3418 $e 20241014 $i 2575-9108 $m ACS pharmacology & translational science $n ACS Pharmacol Transl Sci $x MED00210754
- LZP __
- $a Pubmed-20250117
